Lungcast

With flu season upon us, Dr. Shantanu Agrawal, Chief Health Officer of Anthem Inc., joins us on behalf of their philanthropic arm, Anthem Foundation, to converse about the importance of flu vaccines as a key social driver of health. This episode explores the various vaccination modalities and related public health guidelines, as well as how our joint Fund Off Flu campaign aims to increase influenza knowledge and vaccination rates.

In recognition of Lung Cancer Awareness Month, this episode featuring Dr. James Mulshine at Rush University explains the ins and outs of the improved 2021 lung cancer screening guidelines. While a big step in the right direction, complexities and challenges of equitable access to low-dose CT scans continue to persist, plus the profound impact of the COVID-19 pandemic on screening rates.

Learn more about lung cancer screening at HCPLive.com and Lung.org.

Interstitial lung disease, which prominently includes idiopathic pulmonary fibrosis, is a very broad category of chronic lung conditions with considerable nuance. To help break it down within the context of diagnosis and treatment, Dr. Marilyn Glassberg at University of Arizona joins us to discuss the roles of biomarkers, biopsies and drugs. This episode also sheds light on multidisciplinary clinics and stem cell therapy.

Learn more about ILD and IPF at HCPLive.com and Lung.org.

In this timely episode, we are joined by infectious disease experts Dr. Michael Greenberg of Sanofi Pasteur and Dr. Richard (Rick) Nettles of Johnson & Johnson to discuss respiratory virus immunization. 

It touches upon many hot topics, including the inadvertent health consequences of the pandemic. Additionally, they offer fascinating insight into how unprecedented collaboration and transparency have raised the research bar.

Dr. Castro and Dr. Rizzo discuss the evolving world of monoclonal antibodies for the treatment of severe asthma. Plus, the ALA team discusses September's annual Asthma Peak Week, and what it means for reopening schools.

See and read more Lungcast recaps and additional interviews at HCPLive.com/sap-partner/american-lung-association.

Listen to Dr. Rizzo's interview with Dr. Anne Dixon on the 2020 asthma management guidelines here.

Visit Lung.org for more resources and expert insights into respiratory disease management.

Episode highlights

0:15 Back to school with Asthma Peak Week

9:48 Biologics: the emerging severe asthma treatment field

11:34 Defining type 2 inflammation and severe asthma

15:47 Severe asthma biomarkers

21:23 IL-4, IL-13, TSLP: Promising pathways

25:49 Severe asthma diagnostic clues

28:34 Asthma biologic decision-making

35:31 How long-term is a biologic therapy?

37:44 The future of asthma-modifying therapy

41:09 Understanding asthmatic COVID-19 risk

44:57 Outro

Data beget progress. Such is the promise and hope of artificial intelligence, particularly machine learning, to match lung cancer patients with their optimal treatments.

In this episode, Dr. Andrea Mazzocchi, Co-founder and CEO of Known Medicine, dissects the art and the science of how profiling biomarkers, epigenetics and the microenvironment may provide the synergy needed to revolutionize the oncologic landscape.

The NIH expert joins to highlight the most recent science and understood harms of current e-cigarette devices—and his team's work toward a standardized option for users.

A couple of climate change health experts and advocates join for a timely discussion on the clinical impact of pollution and air quality.

A trio of experts from the Cleveland Clinic join Dr. Rizzo for a talk on lung transplant trends and challenges in the US.

CDC tuberculosis lead Dr. Phillip LoBue joins to discuss the past and present issues of the disease, in time for TB Awareness Day on March 24.